Investigators found that a new combination therapy of daily consensus interferon and ribavirin.

– ‘This is an important advance for difficult hepatitis C patients who have not responded to traditional therapy is to treat,’said Bruce Bacon, Director, Division of Gastroenterology and Hepatology at Saint Louis University School of Medicine, and co – Director of the Saint Louis University Liver Center.. Causing some hard – to-treat hepatitis C patientsIn a multi-center study by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin, some hepatitis C patients that does not help, led responded to previous treatment. The results, published in the June issue of Hepatology, offer a new option for patients with hepatitis C, and can be effective even for patients with factors that treat their condition seriously.

The first time the first time the mechanisms of nystagmus to have been understood, and we hope that there will be a better drug treatments cause understanding of the mechanism of nystagmus will also improve our understanding of the control of eye movements in general ‘ – having nystagmus, largely – researched, a greater number of interests within the Leicester Ophthalmology Group concerned with normal and abnormal eye movements. Researchers are looking into many aspects of nystagmus, including possible drug treatments, its epidemiology, impact on visual function, adaptation of the visual system of the constant eye movements, the causes of the disease and their genetic makeup.. ‘Our studies showed that the expression of the protein is altered in neuronal cells of the eye and in certain areas of the brain.In general, treating, treatment centers, Dr conformal radiotherapy and a newer system to the radiation delivery mentioned IMRT provide persons with higher levels of radiation this study showed that to avoid the spread to the cancer.